Abstract
BACKGROUND: Methotrexate is a cytostatic drug belonging to the group of antimetabolites; it is an antagonist of folic acid with an intensive application in gynecology practice. METHODS: The frequency of micronuclei (MN) in peripheral blood lymphocytes of 30 patients with myoma uteri was analyzed before and after intratumoral application of methotrexate (MTX) in total dose from 50 to 115 mg. Analysis of micronuclei was performed by the application of cytokinesis-block technique (CB). RESULTS: Average frequency of MN in lymphocytes of patients before the therapy was 4.6?0.4 MN/1000 analyzed cells. After the completion of therapy with six separate doses during six consecutive menstrual average frequency of MN increased 1.5 times (7.0?0.6) in comparison to control frequency before the therapy. Statistically significant difference (p<0.001) was established by the Student t test. CONCLUSION: Methotrexate intratumoral treatment of the myoma uteri significantly increased micronuclei in peripheral blood lymphocytes.
Highlights
Methotrexate (MTX) is a cytostatic drug belonging to the group of antimetabolites; it is an antagonist of folic acid, which has an intensive application in the treatment of malignant diseases, psoriasis, and rheumatoid arthritis; lately, it has been used as a form of medicamentous treatment of myoma uteri by subendometrial injection [1]
Since 1985, cytokinesis-block micronucleus test (CBMN) in human peripheral blood lymphocytes has been accepted by many laboratories as an optimal method for evaluation of genotoxic effect [2,3]
The aim of our study was to determine MN frequency in peripheral blood lymphocytes of patients diagnosed with myoma uteri, before and after intratumoral application of MTX
Summary
Methotrexate (MTX) is a cytostatic drug belonging to the group of antimetabolites; it is an antagonist of folic acid, which has an intensive application in the treatment of malignant diseases, psoriasis, and rheumatoid arthritis; lately, it has been used as a form of medicamentous treatment of myoma uteri by subendometrial injection [1]. (MN) in peripheral blood lymphocytes of patients as a consequence of intratumoral application in vivo. Since 1985, cytokinesis-block micronucleus test (CBMN) in human peripheral blood lymphocytes has been accepted by many laboratories as an optimal method for evaluation of genotoxic effect [2,3]. The aim of our study was to determine MN frequency in peripheral blood lymphocytes of patients diagnosed with myoma uteri, before and after intratumoral application of MTX. Methotrexate is a cytostatic drug belonging to the group of antimetabolites; it is an antagonist of folic acid with an intensive application in gynecology practice
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
